Pharmaceutical design of antimitotic agents based on combretastatins

H. P. Hsieh, J. P. Liou, N. Mahindroo

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

The design of novel anticancer agents based on the combretastatins, a group of antimitotic agents isolated from the bark of the South African willow tree Combretum caffrum Kuntz, is of considerable contemporary interest. Combretastatin A-4, the most active compound in the group, due to its unique dual features of antitubulin and antivascular properties, has drawn significant attention of medicinal chemists for the design of analogues as novel antitumor agents. To date, 252 references have been published since 1982 and 187 references have been published since 1998 related to combretastatins research. The 102 references related to chemistry efforts can be classified into three different categories including one-atom, two-atom, and three-atom bridgeheads as linker between two aryl rings of combretastatins. This review will particularly elucidate the rationale and strategic tactics towards the development of novel classes of antimitotic agents, based upon combretastatin A-4 as a promising lead.

Original languageEnglish
Pages (from-to)1655-1677
Number of pages23
JournalCurrent Pharmaceutical Design
Volume11
Issue number13
DOIs
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Antimitotic Agents
Antineoplastic Agents
Combretum
Pharmaceutical Preparations
Salix
Research
combretastatin
fosbretabulin

Keywords

  • Antimitotic agents
  • Antivascular
  • Aroylindoles
  • Benzophenones
  • Combretastatin A-4
  • Combretastatins
  • Drug design
  • Tubulin polymerization

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmaceutical design of antimitotic agents based on combretastatins. / Hsieh, H. P.; Liou, J. P.; Mahindroo, N.

In: Current Pharmaceutical Design, Vol. 11, No. 13, 2005, p. 1655-1677.

Research output: Contribution to journalArticle

Hsieh, H. P. ; Liou, J. P. ; Mahindroo, N. / Pharmaceutical design of antimitotic agents based on combretastatins. In: Current Pharmaceutical Design. 2005 ; Vol. 11, No. 13. pp. 1655-1677.
@article{cc5b6e6ae7f74856a080a8d28a24e9be,
title = "Pharmaceutical design of antimitotic agents based on combretastatins",
abstract = "The design of novel anticancer agents based on the combretastatins, a group of antimitotic agents isolated from the bark of the South African willow tree Combretum caffrum Kuntz, is of considerable contemporary interest. Combretastatin A-4, the most active compound in the group, due to its unique dual features of antitubulin and antivascular properties, has drawn significant attention of medicinal chemists for the design of analogues as novel antitumor agents. To date, 252 references have been published since 1982 and 187 references have been published since 1998 related to combretastatins research. The 102 references related to chemistry efforts can be classified into three different categories including one-atom, two-atom, and three-atom bridgeheads as linker between two aryl rings of combretastatins. This review will particularly elucidate the rationale and strategic tactics towards the development of novel classes of antimitotic agents, based upon combretastatin A-4 as a promising lead.",
keywords = "Antimitotic agents, Antivascular, Aroylindoles, Benzophenones, Combretastatin A-4, Combretastatins, Drug design, Tubulin polymerization",
author = "Hsieh, {H. P.} and Liou, {J. P.} and N. Mahindroo",
year = "2005",
doi = "10.2174/1381612053764751",
language = "English",
volume = "11",
pages = "1655--1677",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Pharmaceutical design of antimitotic agents based on combretastatins

AU - Hsieh, H. P.

AU - Liou, J. P.

AU - Mahindroo, N.

PY - 2005

Y1 - 2005

N2 - The design of novel anticancer agents based on the combretastatins, a group of antimitotic agents isolated from the bark of the South African willow tree Combretum caffrum Kuntz, is of considerable contemporary interest. Combretastatin A-4, the most active compound in the group, due to its unique dual features of antitubulin and antivascular properties, has drawn significant attention of medicinal chemists for the design of analogues as novel antitumor agents. To date, 252 references have been published since 1982 and 187 references have been published since 1998 related to combretastatins research. The 102 references related to chemistry efforts can be classified into three different categories including one-atom, two-atom, and three-atom bridgeheads as linker between two aryl rings of combretastatins. This review will particularly elucidate the rationale and strategic tactics towards the development of novel classes of antimitotic agents, based upon combretastatin A-4 as a promising lead.

AB - The design of novel anticancer agents based on the combretastatins, a group of antimitotic agents isolated from the bark of the South African willow tree Combretum caffrum Kuntz, is of considerable contemporary interest. Combretastatin A-4, the most active compound in the group, due to its unique dual features of antitubulin and antivascular properties, has drawn significant attention of medicinal chemists for the design of analogues as novel antitumor agents. To date, 252 references have been published since 1982 and 187 references have been published since 1998 related to combretastatins research. The 102 references related to chemistry efforts can be classified into three different categories including one-atom, two-atom, and three-atom bridgeheads as linker between two aryl rings of combretastatins. This review will particularly elucidate the rationale and strategic tactics towards the development of novel classes of antimitotic agents, based upon combretastatin A-4 as a promising lead.

KW - Antimitotic agents

KW - Antivascular

KW - Aroylindoles

KW - Benzophenones

KW - Combretastatin A-4

KW - Combretastatins

KW - Drug design

KW - Tubulin polymerization

UR - http://www.scopus.com/inward/record.url?scp=18744379774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744379774&partnerID=8YFLogxK

U2 - 10.2174/1381612053764751

DO - 10.2174/1381612053764751

M3 - Article

VL - 11

SP - 1655

EP - 1677

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -